NCT07353827 2026-01-20
FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma
Sun Yat-sen University
Phase 2 Not yet recruiting
Clinical Trials
18 trialsNCT05348811 2026-01-06
HAIC Combined With Donafenib and Sintilimab for Unresectable ICC
Zhongda Hospital
Phase 2 Completed
NCT07157306 2025-09-05
Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06685289 2025-01-28
Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06482086 2024-12-05
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
West China Hospital
Phase 2 Recruiting
NCT05262959 2024-08-13
A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC
Shanghai Zhongshan Hospital
Phase 2 Completed
NCT06512467 2024-07-22
Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06498622 2024-07-12
Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab
Anhui Provincial Hospital
Phase 2 Recruiting
NCT05576909 2023-07-13
Donafenib Combined With Hepatic Artery Chemoembolization for Perioperative Treatment of Liver Transplantation
Beijing Tsinghua Chang Gung Hospital
Phase 2 Unknown
NCT04962958 2023-06-22
Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT05350943 2022-10-18
HAIC Combined With Toripalimab and Donafenib for Advanced BTC
Fudan University
Phase 2 Unknown
NCT05545124 2022-09-19
Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence
Henan Cancer Hospital
Phase 2 Unknown
NCT05507632 2022-08-19
Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma
Nanfang Hospital, Southern Medical University
Phase 2 Not yet recruiting
NCT05493332 2022-08-18
HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT05166772 2021-12-22
Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05161143 2021-12-17
Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05138159 2021-11-30
A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen
Fudan University
Phase 2 Unknown
NCT02870569 2019-03-01
Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2 Completed